Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine
World Journal Of GastroenterologyPeer ReviewedIoannis S. Elefsiniotis2005Journals
Predictive value of serum b2-microglobulin (b2m) levels for virological breakthrough (VB) in HBeAg-negative chronic hepatitis B (CHB) patients under long-term treatment schedules including lamivudine (LAM).
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support